Pfizer Inc. (NYSE:PFE) Shares Bought by Allied Investment Advisors LLC

Allied Investment Advisors LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 3.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 259,203 shares of the biopharmaceutical company’s stock after buying an additional 9,223 shares during the quarter. Allied Investment Advisors LLC’s holdings in Pfizer were worth $7,501,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Wellington Management Group LLP increased its holdings in Pfizer by 4.9% in the fourth quarter. Wellington Management Group LLP now owns 239,209,768 shares of the biopharmaceutical company’s stock valued at $6,886,849,000 after buying an additional 11,099,024 shares during the last quarter. Marshall Wace LLP lifted its stake in Pfizer by 279.3% during the second quarter. Marshall Wace LLP now owns 5,378,173 shares of the biopharmaceutical company’s stock worth $150,481,000 after purchasing an additional 8,378,173 shares during the last quarter. Swedbank AB acquired a new position in Pfizer in the first quarter worth $172,902,000. Pzena Investment Management LLC increased its stake in Pfizer by 181.6% during the first quarter. Pzena Investment Management LLC now owns 7,670,445 shares of the biopharmaceutical company’s stock valued at $212,855,000 after purchasing an additional 4,947,000 shares during the last quarter. Finally, FIL Ltd raised its holdings in shares of Pfizer by 97.1% during the fourth quarter. FIL Ltd now owns 7,582,518 shares of the biopharmaceutical company’s stock worth $218,301,000 after purchasing an additional 3,734,595 shares during the period. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on PFE shares. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Thursday. StockNews.com downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Tuesday. UBS Group upped their price objective on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Finally, Wells Fargo & Company raised their target price on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Nine research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Price Performance

PFE traded up $0.24 during trading on Friday, reaching $28.58. The stock had a trading volume of 28,786,884 shares, compared to its average volume of 37,384,395. The stock has a 50 day moving average of $29.17 and a two-hundred day moving average of $28.31. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $161.95 billion, a price-to-earnings ratio of -476.33, a price-to-earnings-growth ratio of 1.25 and a beta of 0.67. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $33.92.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The business had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.67 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.